Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia (NCT01111981) | Clinical Trial Compass
UnknownPhase 4
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia
United States30 participantsStarted 2009-10
Plain-language summary
The purpose of this study is to ascertain the safety and efficacy of
Clobetasol Propionate 0.05% E Foam in the treatment of Central Centrifugal
Cicatricial Alopecia.
Who can participate
Age range18 Years ā 80 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with CCCA, treated or untreated
* Score 0 - 1 on Scale/Questionnaire
* 18 years of age or older
* Women of African descent
Exclusion Criteria:
* Score \> 1 on Scale/Questionnaire
* Alopecias other than CCCA, including alopecia arreata, lichen planopilaris, trichotillomania, and traction alopecia
* History of hair transplantation
* Children less than 18 years of age
* Males
* Women of non-African descent
* Pregnancy or breastfeeding. Women of childbearing age must use reliable forms of contraception (e.g., abstinence, oral contraceptives, or spermicide and condoms)
* Anti-dandruff shampoo within 30 days
* Anti-inflammatory medications such as antibiotics (doxycycline, minocycline, rifampin, etc.), steroids (oral prednisone, topical corticosteroids,etc.), NSAIDs (ibuprofen, aspirin, etc.)